Statute Details
- Title: Medicines (Advertisement and Sale) Act 1955
- Act Code: MASA1955
- Long Title: An Act to prohibit certain advertisements relating to medical matters and to regulate the sale of substances recommended as a medicine.
- Type: Act of Parliament
- Status: Current version (as at 27 Mar 2026)
- Commencement: [26 June 1956] (as shown in the provided text)
- Key Provisions (from extract):
- Section 3: Prohibition of advertisements relating to certain diseases and conditions (including defences and a Government/public authority carve-out).
- Section 5: Prohibition of advertisements relating to abortion.
- Section 6: Offences, penalties, presumptions, and defences for contraventions of Sections 3 and 5.
- Section 7: Disclosure of composition of medicines (retail sale and samples).
- Section 8: Jurisdiction.
- Section 9: Exemption.
- Schedule: “Diseases and conditions” (and the Minister’s power to amend the Schedule via Gazette notification).
- Related Legislation: Poisons Act 1938 (including the “Poisons List” referenced in the Act).
What Is This Legislation About?
The Medicines (Advertisement and Sale) Act 1955 (“MASA”) is Singapore’s foundational statute addressing two connected regulatory concerns: (1) the advertising of medicines in relation to certain sensitive medical conditions, and (2) the retail sale of substances that are “recommended as a medicine”. In plain terms, it restricts marketing practices that could encourage self-treatment for specified diseases and conditions, and it prohibits advertising that facilitates abortion or miscarriage.
MASA operates by defining what counts as an “advertisement” and what counts as a “substance recommended as a medicine”. It then draws a line between permissible information and prohibited promotional claims. The statute is particularly strict where advertisements relate to (a) diseases and conditions listed in the Schedule, and (b) abortion/miscarriage. It also includes procedural and evidential rules—such as presumptions and defences—that shape how enforcement is conducted.
In addition to advertising restrictions, MASA regulates the sale of certain products by requiring disclosure of composition. This is designed to protect consumers and to ensure that retail buyers and those receiving samples are not misled about what they are purchasing or being induced to buy.
What Are the Key Provisions?
1) Definitions and the scope of “advertisement” and “substance recommended as a medicine” (Section 2)
Section 2 is critical because it determines what activities and products fall within MASA. The Act defines “advertisement” broadly: it includes notices, circulars, pamphlets, labels, wrappers, other documents, oral announcements, and any form of advertising by producing or transmitting light or sound. This breadth matters for modern marketing channels (e.g., print, packaging, audio-visual media, and other forms of promotion), because the definition is not limited to traditional newspapers or posters.
The Act also defines “substance recommended as a medicine” by reference to how the substance is presented. It covers substances referred to on the article itself, wrappers/containers, labels, enclosed documents, placards exhibited at the place of sale, and advertisements published after the Act’s passing by relevant parties (manufacturer, seller, or proprietor of a proprietary designation). The key functional test is whether the terms are “calculated to lead to the use of the substance for the prevention or treatment” of ailments, infirmities, or injuries affecting the human body—while excluding terms that give a definite indication the substance is intended as food or drink, and excluding terms that indicate it is, or is part of, a medicine.
2) Prohibition of advertisements relating to certain diseases and conditions (Section 3)
Section 3(1) provides the core advertising prohibition. Subject to the Act, no person shall take part in publishing an advertisement referring to an article (or articles) in terms calculated to lead to the use of that article as a medicine, appliance, or remedy for treatment of human beings for any disease or condition set out in the Schedule.
Two practical points follow from this structure. First, the prohibition is not limited to “medicines” in a narrow pharmaceutical sense; it can capture articles marketed as remedies for listed conditions. Second, the test is “calculated to lead to the use” for treatment—so intent and effect are assessed through the marketing language and its likely influence.
Government/public authority carve-out: Section 3(1) contains a proviso that the subsection does not apply to advertisements published by the Government or public authority, or by the governing body of a public hospital, or by a person authorised by the Minister. This supports public health communications and institutional notices, while keeping private commercial promotion tightly controlled.
Defence for targeted publication to specified professional groups (Section 3(2)): In proceedings for contravention of Section 3(1), the charged person may rely on a defence by proving that the advertisement was published only as reasonably necessary to bring it to the notice of certain classes, including members of local/public authorities, governing bodies of public hospitals, registered medical practitioners, registered dentists, registered nurses and midwives, registered pharmacists and holders of licences to sell poisons set out in the Poisons Act 1938, and persons undergoing training to become those professionals. This defence is important for industry communications, but it is narrow: it requires publication limited to the specified classes and only to the extent reasonably necessary.
3) Prohibition of advertisements relating to abortion (Section 5)
Section 5 prohibits taking part in publishing advertisements that refer to any skill or service, or to any article, in terms calculated to induce a person to seek the advertiser’s advice in connection with such skill/service, or to lead to the use of the article for procuring miscarriage of women. The provision is drafted to capture both direct product promotion and “advice-seeking” marketing strategies.
Unlike Section 3, Section 5 does not depend on a Schedule of diseases/conditions. It is a categorical prohibition tied to the purpose of procuring miscarriage. For practitioners, this means that even if the product is not marketed for a Schedule-listed condition, abortion-related advertising remains prohibited if it meets the statutory description.
4) Offences, penalties, presumptions, and defences (Section 6)
Section 6(1) sets out penalties for contraventions of Sections 3 or 5. On a first conviction, liability may include a fine not exceeding $1,000, or imprisonment not exceeding one year, or both. On subsequent convictions, the maximum fine increases to $2,000 and imprisonment to two years, or both. While these amounts reflect older legislative drafting, the provision remains significant for compliance risk assessment.
Presumption of “taking part” in publication (Section 6(2)): Section 6(2) provides an evidential mechanism. If it is proved that (a) an advertisement was published in terms calculated to lead to treatment for Schedule-listed diseases (Section 3) or to procuring miscarriage (Section 5), and (b) the advertisement also indicated that the article was manufactured/produced/imported/sold/offered for sale by the person charged, then—unless the contrary is proved—it is presumed that the person took part in the publication. This shifts the burden to the charged person to rebut the presumption.
Defences (Section 6(3)): Section 6(3) provides two defences. The first is lack of knowledge and no reason to believe the person was taking part in publication. The second is a publication-in-technical-context defence: the advertisement was published only in a technical publication intended for circulation mainly among specified professional classes (mirroring the classes in Section 3(2)). This defence is particularly relevant for trade journals, professional bulletins, and communications that are genuinely technical and restricted to healthcare professionals.
5) Disclosure of composition for retail sale and samples (Section 7)
Section 7 addresses the sale side of MASA. It prohibits, subject to the Act, any person from (a) selling by retail any article consisting of or comprising a substance recommended as a medicine, or (b) supplying such an article as a sample for the purpose of inducing persons to buy by retail, unless there is written disclosure of the composition of the medicine. The provided extract truncates the remainder of Section 7, but the structure is clear: it imposes a mandatory disclosure requirement as a condition of lawful retail sale and sample supply.
For practitioners, the key compliance question is what “written” disclosure is required, in what languages, and how it must be presented on or with the product. Section 7(1) indicates that disclosure must be in English and also in any other language used in addition to English, and it must be “clearly” presented (the extract cuts off mid-sentence). In practice, this means packaging, labels, inserts, and promotional materials for retail sale must be reviewed for compliance with the disclosure format and content requirements.
6) Jurisdiction and exemptions (Sections 8 and 9)
Section 8 concerns jurisdiction—i.e., which courts or authorities have power to hear offences under the Act. Section 9 provides for exemptions. While the extract does not set out the text of these sections, their presence signals that MASA is not absolute: there are circumstances where conduct may be exempted, and enforcement is channelled through defined jurisdictional rules.
How Is This Legislation Structured?
MASA is structured as a short, targeted regulatory statute with a small number of operative provisions:
Sections 1–2 cover the short title and interpretation, including broad definitions that determine the Act’s reach.
Section 3 sets out the prohibition on advertisements relating to diseases and conditions listed in the Schedule, including a Government/public authority carve-out and a professional-targeting defence.
Section 4 is repealed (as indicated by the extract).
Section 5 prohibits advertisements relating to abortion/miscarriage.
Section 6 provides offences, penalties, presumptions, and defences for contraventions of Sections 3 and 5.
Section 7 regulates retail sale and sample supply by requiring disclosure of composition.
Sections 8–9 address jurisdiction and exemptions.
The Schedule lists the diseases and conditions to which Section 3 applies, and the Minister has power to add, vary, or amend the Schedule by Gazette notification.
Who Does This Legislation Apply To?
MASA applies broadly to “no person” taking part in the publication of prohibited advertisements and to persons who sell or supply retail products that are “substances recommended as a medicine”. This includes manufacturers, sellers, advertisers, proprietors of proprietary designations, and potentially publishers or intermediaries who “take part” in publication.
However, the Act also recognises practical realities by providing limited defences tied to publication to specified professional groups (registered medical practitioners, dentists, nurses/midwives, pharmacists/licensed poison sellers, and trainees). It also provides a carve-out for Government/public authority and public hospital-related advertisements authorised by the Minister. Accordingly, the compliance obligations are not confined to healthcare institutions; private commercial actors and marketers are directly exposed.
Why Is This Legislation Important?
MASA is important because it targets the risk of harmful self-treatment and misleading medical marketing. By prohibiting advertisements for Schedule-listed diseases and conditions, it reduces the likelihood that consumers will rely on promotional claims rather than professional diagnosis and treatment. The abortion/miscarriage prohibition reflects the legislature’s strong policy stance against commercial facilitation of unlawful or harmful reproductive outcomes.
From an enforcement perspective, Section 6’s presumptions and defences are central. The presumption that a person “took part” in publication—where the advertisement both promotes treatment for a relevant condition and indicates the charged person’s role in manufacturing/selling—can significantly affect litigation strategy and evidential burdens. Practitioners should therefore treat advertising compliance as a matter of both substantive risk (what is being claimed) and procedural risk (how evidence will be framed in court).
Finally, the retail sale and composition disclosure requirement in Section 7 is a consumer-protection tool. Even where advertising may be less direct, retail sale and sample supply can trigger MASA obligations. For businesses, this means compliance cannot be limited to advertising copy; it must extend to packaging, labels, inserts, and sample distribution practices.
Related Legislation
- Poisons Act 1938 (including the “Poisons List” referenced in MASA, and the licensing context for pharmacists and poison sellers)
Source Documents
This article provides an overview of the Medicines (Advertisement and Sale) Act 1955 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the official text for authoritative provisions.